Solid tumor is a highly unmet needs area. If PH1 OnCarlytics with whatever combo should show 'significant tumor killing or obliteration of tumor', the FDA will fast track them through a registrational PH2/3 trials. And I believe this is being planned for by this deal with ABL. From what they have seen, they must be very confident of that to make this deal and then even mentioned Ph2/3 and registrational trials in the ABL announcement. It was not mentioned in passing but for a purpose/hint to the shareholders who are willing to think a bit deeper.
In addition, it looks like the in lab trial has shown CF33/OnCarlytics to work with different CD-19 targeted therapy. If the unveiling of those 3 abstracts in SITC proves that, I believe most, if not all, CD-19 targeted approved therapy out there would want to collaborate with IMU. Either that or be left behind by those who has a deal with IMU.
Seriously, if the data truly shows significant tumor killing as mentioned by LC, it will make world headlines as promised by Bob Hariri.
Media Thread, page-6959
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.6¢ |
Change
0.001(2.22%) |
Mkt cap ! $342.1M | |||
| Open | High | Low | Value | Volume |
| 4.5¢ | 4.7¢ | 4.5¢ | $906.2K | 19.67M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 9543864 | 4.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.6¢ | 1266571 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |